Y-Biologics, a leader in antibody-based drug platforms, announced on May 28th the signing of a Memorandum of Understanding (MOU) with LigaChem Biosciences (CEO Yong-Ju Kim) to strategically collaborate in the field of Antibody-Drug Conjugates (ADC).

This partnership aims to enhance joint research and development of ADCs, solidifying their position in the global biopharmaceutical market. The collaboration will focus on several key projects, including:

① Joint R&D of ADCs targeting two new targets

② Joint R&D of pH-sensitive antibody-based ADCs

③ Joint R&D of bispecific antibody-based ADCs

④ Joint R&D of single or bispecific antibody-based antibody-immunomodulatory drug conjugates

Building on a partnership established in 2016, the companies have previously co-developed 'YBL-001(LCB67)', an ADC anti-cancer candidate targeting DLK1, which was successfully out-licensed to Pyxis Oncology in the United States in 2020. This new agreement aims to accelerate the development of additional innovative ADCs.

Young-Woo Park, CEO of Y-Biologics, stated, "We are pleased to continue our strategic cooperation with LigaChem Biosciences and will do our utmost to jointly develop new ADC therapeutics with global competitiveness."

Yong-Ju Kim, CEO of LigaChem Biosciences, added, "Through this agreement, we will strengthen our strategic partnership with Y-Biologics and create opportunities for mutual growth through close cooperation."